2-hydroxypropane-1,2,3-tricarboxylic acid; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile
Title | Journal |
---|---|
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. | Journal of Crohn's & colitis 20180101 |
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. | Gut 20170601 |
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. | The New England journal of medicine 20170504 |
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. | Arthritis & rheumatology (Hoboken, N.J.) 20170101 |
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells. | Toxicological sciences : an official journal of the Society of Toxicology 20170101 |
Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). | Future medicinal chemistry 20160901 |
Tofacitinib for the treatment of psoriasis. | Expert opinion on pharmacotherapy 20160701 |
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. | Rheumatology (Oxford, England) 20160601 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. | Journal of the American Academy of Dermatology 20160501 |
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. | The Journal of allergy and clinical immunology 20160401 |
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. | Blood 20160310 |
Elucidating the Mechanism of Tofacitinib Oxidative Decyanation. | Drug metabolism letters 20160101 |
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. | Clinical and experimental rheumatology 20160101 |
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. | European journal of pharmacology 20151015 |
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS). | Journal of clinical immunology 20151001 |
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. | Oncotarget 20150821 |
Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes. | Modern rheumatology 20150701 |
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. | Annals of the rheumatic diseases 20150601 |
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. | Leukemia 20150401 |
White-to-brown metabolic conversion of human adipocytes by JAK inhibition. | Nature cell biology 20150101 |
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. | Arthritis research & therapy 20150101 |
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. | The Journal of investigative dermatology 20141201 |
Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. | Journal of medicinal chemistry 20140626 |
Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. | The Journal of investigative dermatology 20140401 |
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. | Antimicrobial agents and chemotherapy 20140401 |
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. | Leukemia 20140201 |
Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity. | Cornea 20140201 |
IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. | Journal of immunology (Baltimore, Md. : 1950) 20140101 |
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. | Journal of immunology research 20140101 |
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma. | Toxicology and applied pharmacology 20131215 |
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. | Clinical and experimental immunology 20131201 |
Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. | Journal of clinical immunology 20130401 |
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. | Arthritis and rheumatism 20121201 |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. | Arthritis and rheumatism 20121101 |
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120901 |
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. | The British journal of dermatology 20120901 |
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | The New England journal of medicine 20120816 |
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. | The New England journal of medicine 20120809 |
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. | The New England journal of medicine 20120809 |
[Janus kinase inhibitors]. | Zeitschrift fur Rheumatologie 20120801 |
Tofacitinib for the treatment of moderate to severe rheumatoid arthritis. | Drugs of today (Barcelona, Spain : 1998) 20120801 |
Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. | British journal of clinical pharmacology 20120701 |
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. | Cancer discovery 20120701 |
Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. | British journal of pharmacology 20120601 |
Novel small-molecular therapeutics for rheumatoid arthritis. | Current opinion in rheumatology 20120501 |
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. | Arthritis and rheumatism 20120401 |
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. | Annals of the rheumatic diseases 20120401 |
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. | Annals of the rheumatic diseases 20120301 |
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. | PloS one 20120101 |
Targeting JAK3 in kidney transplantation: current status and future options. | Current opinion in organ transplantation 20111201 |
Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. | The Journal of rheumatology 20111101 |
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. | International immunology 20111101 |
A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants. | Journal of clinical pharmacology 20110901 |
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. | Arthritis care & research 20110801 |
Current landscape for T-cell targeting in autoimmunity and transplantation. | Immunotherapy 20110701 |
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). | Journal of immunology (Baltimore, Md. : 1950) 20110401 |
Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. | Journal of medicinal chemistry 20110113 |
CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. | Arthritis research & therapy 20110101 |
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production. | BMC immunology 20110101 |
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. | Journal of medicinal chemistry 20101223 |
Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. | Therapeutic drug monitoring 20101201 |
Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. | Kidney international. Supplement 20100901 |
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. | Best practice & research. Clinical rheumatology 20100801 |
Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. | Journal of molecular biology 20100716 |
Novel immunosuppressive agents in kidney transplantation. | Clinical nephrology 20100501 |
A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors. | Journal of immunological methods 20100331 |
Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. | Transplantation 20091027 |
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090801 |
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. | Arthritis and rheumatism 20090701 |
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. | Journal of clinical pharmacology 20090401 |
The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. | Transplantation 20090115 |
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). | Journal of medicinal chemistry 20081225 |
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20080801 |
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. | Cancer science 20080601 |
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. | European journal of pharmacology 20080317 |
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. | Arthritis research & therapy 20080101 |
Arthritis clinical trial results revealed. | JAMA 20070103 |
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. | Transplantation 20051227 |
Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. | Transplantation 20051115 |
JAK protein kinase inhibitors. | Drug news & perspectives 20050601 |
Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. | Transplantation 20050415 |
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. | Journal of leukocyte biology 20041201 |
JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. | Trends in molecular medicine 20041101 |
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. | Science (New York, N.Y.) 20031031 |